Recent Updates
Recently added Catalysts
ATHE Neutral Sentiment Score: 60/100

Confidential Appendix 3Y Change of Director's Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director's Interest Notice Information or documents not available now must be given to ASX as soon as available. Informatio

Thursday, January 11, 2024 2 min read
Key Takeaway: Alterity Therapeutics Limited announced changes in directors' interests, specifically involving Mr. Peter Marks and Mr. Brian Meltzer. Both directors acquired additional shares that were unlisted options through a placement approved at the extraordinary general meeting held on December 29, 2023. Their total direct and indirect interests were updated accordingly, reflecting a significant retention of shares, which may imply confidence in the company's strategy moving forward.

Market Sentiment Analysis

POSITIVE FACTORS

  • Change of director's interests indicates ongoing activity within the company.
  • Approval of share allocation shows potential for future growth.
  • Directors acquiring additional shares can signify confidence in the company's direction.

Full Press Release Details

Change of Director's
of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property
and may be made public.
30/9/2001. Amended 01/01/11
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ABN: 37 080 699 065
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
Name of Director: Mr. Peter Marks
Date of Last Notice: 15 December 2022
1 - Change of director's relevant interests in securities
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director"
should be disclosed in this part.
Direct or indirect interest Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Related entity
Date of change 08 January 2024
No. of securities held prior to change
Shares Options
Direct - 7,000,000
Indirect 43,111
Total 43,111 7,000,000
Class Unlisted Options
Number acquired
Shares Options
Direct -
Indirect 7,142,857 9,523,809
Total 7,142,857 7,142,857
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation A$0.0035 per share with free attaching per Notice of EGM held 29 December 2023
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Change of Director's
No. of securities held after change
Shares Options
Direct - 7,000,000
Indirect 7,185,986 9,523,809
Total 7,185,968 16,523,809
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of shares and options under placement approved at the EGM held 29 December 2023
2 - Change of director's interests in contracts
In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director"
should be disclosed in this part.
Detail of contract
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011
Change of Director's
of Director's Interest Notice
or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property
and may be made public.
30/9/2001.. Amended 01/01/11
Name of Entity: Alterity Therapeutics Limited (ASX:ATH)
ABN: 37 080 699 065
(the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section
205G of the Corporations Act.
Name of Director: Mr. Brian Meltzer
Date of Last Notice: 15 December 2022
1 - Change of director's relevant interests in securities
the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director"
should be disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Related entity
Date of change 08 January 2024
No. of securities held prior to change
Shares Options
Direct - 7,000,000
Indirect 326,666 -
Total 326,666 8,250,000
Class Unlisted Options
Number acquired
Shares Options
Direct 7,142,857 9,523,809
Indirect - -
Total - -
Number disposed
Shares Options
Direct - -
Indirect - -
Total - -
+ See chapter 19 for defined terms.
11/3/2002 Appendix 3Y Page 1
Change of Director's
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation A$0.0035 per share with free attaching per Notice of EGM held 29 December 2023
No. of securities held after change
Shares Options
Direct 7,142,857 16,523,809
Indirect 326,666 -
Total 7,469,523 16,523,809
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of shares and options under placement approved at the EGM held 29 December 2023
2 - Change of director's interests in contracts
In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director"
should be disclosed in this part.
Detail of contract N/A
Nature of interest
Name of registered holder (if issued securities)
Date of change
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired
Interest disposed
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change
Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No
If so, was prior written clearance provided to allow the trade to proceed during this period? N/A
If prior written clearance was provided on what date was this provided? N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2 01/01/2011

Frequently Asked Questions

What is the entity reported in the notice?

The entity is Alterity Therapeutics Limited (ASX:ATH).

Who is the director mentioned in the notice?

The directors mentioned are Mr. Peter Marks and Mr. Brian Meltzer.

When did the changes in director's interests occur?

The changes occurred on 08 January 2024.

How many shares did Mr. Marks hold after the change?

Mr. Marks held 7,185,968 shares after the change.

What was the consideration for the acquired shares?

The consideration was A$0.0035 per share with free attaching.

Tags: ATHE Viatris Investor Conferences Healthcare Alterity Therapeutics director interests Peter Marks Brian Meltzer ATH
Last updated: Jan 11, 2024